Colgate and ADA team up
This article was originally published in The Rose Sheet
Executive SummaryColgate-Palmolive has signed on to be a national strategic partner of the American Diabetes Association, backing ADA's oral-care activities "which will seek to further the understanding of the connection between oral health and diabetes," according to April 2 release. ADA and Colgate will collaborate on educating patients, healthcare professionals and the public about the "importance of good oral care for people with diabetes" and for those at risk of developing the disease. Diabetes patients are estimated to be 2 to 5 times more likely to develop gum disease than people without diabetes, according to the association. Colgate additionally will support ADA's "Ask the Dentist" online chat series and the oral hygiene section of 1www.diabetes.org...
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.